{"schema_version":"secwatch.filing_event.v1","accession":"0001297184-23-000026","form_type":"8-K","ticker":"AMPH","cik":"0001297184","company_name":"Amphastar Pharmaceuticals, Inc.","filed_at":"2023-03-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:44.268807+00:00","generated_at":"2026-06-18T05:16:45.124596+00:00","sec_items":["1.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"confidence":"high","headline":"Amphastar enters $0.5M amendment with related party Hanxin for insulin R&D scale-up","bullets":["Amendment to Contract Research Agreement dated July 5, 2022 with Nanjing Hanxin Pharmaceutical Technology Co., Ltd.","Hanxin will perform scale-up manufacturing process development using Recombinant Human Insulin Research Cell Banks (RCBs).","Total cost not to exceed approximately $0.5 million; payments in Chinese yuan adjusted for exchange rates.","Related party transaction: CEO Jack Zhang and Chairman Mary Luo beneficially own majority of Hanxin; Audit Committee approved.","Agreement term matches original contract, currently through July 5, 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001297184-23-000026","json":"https://secwatch.observer/filing/0001297184-23-000026.json","markdown":"https://secwatch.observer/filing/0001297184-23-000026.md","text":"https://secwatch.observer/filing/0001297184-23-000026.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1297184/000129718423000026/0001297184-23-000026-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1297184/000129718423000026/amph-20230308x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T05:16:45.124596+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4d30021e351c47013e1cc8d84c0a931fd82ebe2c","claim":"Amphastar Pharmaceuticals, Inc. amended Contract Research Agreement with Nanjing Hanxin Pharmaceutical Technology Co., Ltd. valued at not exceed approximately $0.5 million (effective 2023-03-08).","evidence_excerpt":"On March 8, 2023, Amphastar Pharmaceuticals, Inc. (together with its subsidiaries, the “Company”) and Nanjing Hanxin Pharmaceutical Technology Co., Ltd. (“Hanxin”) entered into an Amendment to that certain Contract Research Agreement by and between the Company and Hanxin, dated July 5, 2022 (the “Amendment”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1297184/000129718423000026/0001297184-23-000026-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"amendment"},{"label":"Agreement","value":"license"},{"label":"Counterparty","value":"Nanjing Hanxin Pharmaceutical Technology Co., Ltd."},{"label":"Value","value":"not exceed approximately $0.5 million"},{"label":"Effective","value":"2023-03-08"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}